@misc{ersoy_yılmaz_ceylaner_2020, 
  title={Antioxidant therapy in a patient with Hyperprolinemia type I presented with mild neuromotor retardation and speech disturbance}, 
  DOI={10.21203/rs.3.rs-128629/v1}, 
  abstractNote={<jats:title>Abstract</jats:title>
        <jats:p>Background: Hyperprolinemia type 1 (HPI) is an autosomal recessive inborn disease caused by mutations/deletions of PRODH gene, which is located on chromosome 22q11. The clinic spectrum involves mainly delayed psychomotor development, mild-to-severe mental retardation, neuropsychiatric symptoms and epilepsy. Although HPI can easily be diagnosed in patients undergoing metabolic screening tests, there is no effective therapy protocol in use. There are studies showing that it does most of its clinical findings by disrupting mitochondria function. Case report: We present a long-term follow-up of a four-year-old girl with mild neuromotor retardation and speech disturbance, diagnosed with HPI and treated with antioxidant therapy (vitamin C, CoenzymeQ10, vitamin B complex and L-carnitine) for six years. It has been shown that antioxidant therapy decreases proline levels properly and provides clinical improvement.</jats:p>}, 
  publisher={Research Square}, 
  author={Ersoy, Melike and Yılmaz, Semra and Ceylaner, Serdar}, 
  year={2020}, 
  month={Dec}
  }